ArticleNature communications2015
A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected].
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Graphdiyne biomaterials: from characterization to properties and applications.Journal of nanobiotechnology · 2025Review
- Optical properties of nanostructured antiviral and anticancer drugs.RSC advances · 2023Article
- Conjugated Polymeric Materials in Biological Imaging and Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- A ratiometric fluorescent sensor for detection of metformin based on terbium-1,10-phenanthroline-nitrogen-doped-graphene quantum dots.RSC advances · 2022Article
- Magnetic Nanoparticle-Mediated Heating for Biomedical Applications.Journal of heat transfer · 2022Article
- Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor.Asian journal of pharmaceutical sciences · 2021Review
- Lipid-Based Nanocarriers for The Treatment of Glioblastoma.Advanced nanobiomed research · 2021Article
- Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance.Nature communications · 2021Article
- Heterofullerene MCNanomaterials (Basel, Switzerland) · 2021Article
- Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy.Advanced healthcare materials · 2020Article
- Recent Advances in Rare-Earth-Doped Nanoparticles for NIR-II Imaging and Cancer Theranostics.Frontiers in chemistry · 2020Review
- Nanoparticles of Antroquinonol-Rich Extract from Solid-State-CulturedInternational journal of nanomedicine · 2020Article
- Inhibition of CaMKIIα Activity Enhances Antitumor Effect of Fullerene C60 Nanocrystals by Suppression of Autophagic Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Insight into the preformed albumin corona onAsian journal of pharmaceutical sciences · 2019Article
- Stacking of doxorubicin on folic acid-targeted multiwalled carbon nanotubes for in vivo chemotherapy of tumors.Drug delivery · 2018Article
- Enhanced cancer therapy with cold-controlled drug release and photothermal warming enabled by one nanoplatform.Biomaterials · 2018Article
- MHI-148 Cyanine Dye Conjugated Chitosan Nanomicelle with NIR Light-Trigger Release Property as Cancer Targeting Theranostic Agent.Molecular imaging and biology · 2018Article
- NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer.Nature communications · 2018Article
- Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial.ACS central science · 2018Article
- Synthesis, Optical, and Structural Studies of Iron Sulphide Nanoparticles and Iron Sulphide Hydroxyethyl Cellulose Nanocomposites from Bis-(Dithiocarbamato)Iron(II) Single-Source Precursors.Nanomaterials (Basel, Switzerland) · 2018Article
Corrections and comments
- Erratum issued
- Retracted
Authors and funding
6 authors.
Funding
Abstract
Nanoparticles have demonstrated great potential for enhancing drug delivery. However, the low drug encapsulation efficiency at high drug-to-nanoparticle feeding ratios and minimal drug loading content in nanoparticle at any feeding ratios are major hurdles to their widespread applications. Here we report a robust eukaryotic cell-like hybrid nanoplatform (EukaCell) for encapsulation of theranostic agents (doxorubicin and indocyanine green). The EukaCell consists of a phospholipid membrane, a cytoskeleton-like mesoporous silica matrix and a nucleus-like fullerene core. At high drug-to-nanoparticle feeding ratios (for example, 1:0.5), the encapsulation efficiency and loading content can be improved by 58 and 21 times, respectively, compared with conventional silica nanoparticles. Moreover, release of the encapsulated drug can be precisely controlled via dosing near infrared laser irradiation. Ultimately, the ultra-high (up to ∼87%) loading content renders augmented anticancer capacity both in vitro and in vivo. Our EukaCell is valuable for drug delivery to fight against cancer and potentially other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.